Skip to main navigation Skip to search Skip to main content

A 5-year cost-effectiveness analysis of silicone metacarpophalangeal arthroplasty in patients with rheumatoid arthritis

  • Lee Squitieri
  • , Kevin C. Chung
  • , David W. Hutton
  • , Patricia B. Burns
  • , H. Myra Kim
  • , Elham Mahmoudi

Research output: Contribution to journalArticlepeer-review

Abstract

Background: There is a paucity of research evaluating the cost-effectiveness of surgical interventions for rheumatoid arthritis patients. Previous reports have challenged the sustainability of improved outcomes after silicone metacarpophalangeal arthroplasty. The authors conducted an economic evaluation of the long-term health outcomes after silicone metacarpophalangeal arthroplasty. Methods: The authors performed a 5-year prospective cohort study of 170 patients with rheumatoid arthritis (73 surgical and 97 nonsurgical). Objective functional measurements and patient-rated outcomes using the Michigan Hand Outcomes Questionnaire and the Arthritis Impact Measurement Scale 2 were collected at 3 and 5 years. A cost-effectiveness analysis using direct costs from Medicare outpatient claims data (2006 to 2010) was performed to estimate the incremental cost-effectiveness ratios for both the Michigan and Arthritis Impact Measurement Scale 2 measurements. Results: At 5 years, the authors observed a statistically significant difference in upper extremity outcomes (Michigan Hand Outcomes Questionnaire) between the two groups, with surgical patients having higher outcomes. Costs associated with improved outcomes 5 years after surgery were $787 to $1150 when measured by the Michigan Hand Outcomes Questionnaire and $49,843 to $149,530 when measured by the Arthritis Impact scale. The incremental cost-effectiveness ratios did not substantially increase with their observed surgical revision rate of 5.5 percent (approximately 4 percent increase in incremental cost-effectiveness ratio) or with previously published long-term revision rates of 6.2 percent (approximately 6 percent increase in incremental cost-effectiveness ratio). Conclusions: Short-term improvements in upper extremity outcomes after silicone metacarpophalangeal arthroplasty are maintained over the 5-year follow-up period. These outcomes are achieved at a relatively low cost, even with the addition of potential surgical complications.

Original languageEnglish (US)
Pages (from-to)305-314
Number of pages10
JournalPlastic and reconstructive surgery
Volume136
Issue number2
DOIs
StatePublished - Aug 31 2015
Externally publishedYes

ASJC Scopus subject areas

  • Surgery

Fingerprint

Dive into the research topics of 'A 5-year cost-effectiveness analysis of silicone metacarpophalangeal arthroplasty in patients with rheumatoid arthritis'. Together they form a unique fingerprint.

Cite this